HomePink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo
Email Preferences
Free Trial
Email Preferences
Free Trial
Spotlight
  • China
  • FDA
  • EU Regulatory Reform
  • AI
  • Cell & Gene Therapy
  • Interviews

Policy & Regulation
  • Product Reviews
  • IP & Litigation
  • Drug Safety
  • Regulatory Pathways
  • Legislation
Market Access
  • HTA
  • PBMs
  • Medicaid
  • Medicare

Regions
  • Cross-Agency Comparisons
  • Asia
  • North America
  • Europe
  • Latin America
  • Middle East & Africa
  • Global Guidance Tracker
FDA Tools & Trackers
  • User Fee Goal Dates
  • Novel Approvals
  • Designations
  • Complete Response Letters
  • US Biosimilars
  • Advisory Committee Meetings

EMA Tools & Trackers
  • EU Filings
  • CHMP Opinions
  • EU Approvals
  • Accelerated Assessment
  • EU Biosimilars
  • PRIME Scheme
Podcasts

Conference Coverage

Partner Insights

Advertise

Pink Sheet Perspectives

Previewing major regulatory, market access and political themes.

View

Pink Sheet

Scrip

Medtech Insight

HBW Insight

Generics Bulletin

In Vivo
Pink Sheet logo
  1. Home
  2. >>Pink Sheet
  3. >>Legislation

Legislation

ElectionsEU Regulatory Reform
  • Coping Strategies For China Industry Amid BIOSECURE Overhang

    Coping Strategies For China Industry Amid BIOSECURE Overhang

    Nov 10 2025 
    • By Xu Hu

    With the US BIOSECURE Act waiting for a Senate vote, there are signs it may be prompting some Chinese firms to look at their operations. In the meantime, two legal experts in China suggest a range of coping strategies for companies that may be deemed "of concern."

  • EU Pharma Reform: What You Need to Know Now

    EU Pharma Reform: What You Need to Know Now

    Oct 08 2024 
    • By Anabel Costa-Ferreira and Ian Schofield

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • PBM Legislation: Medicare Rebate Reform May Be Challenging Amid Disruption From Redesign

    PBM Legislation: Medicare Rebate Reform May Be Challenging Amid Disruption From Redesign

    Sep 09 2024 
    • By Cathy Kelly

    US lawmakers will undoubtedly continue to work on pharmacy benefit manager reform legislation in 2025, given its bipartisan support. But policies impacting rebates that could lead to higher premiums in Part D may be a tough sell in the midst of the benefit redesign.

  • US Presidential Elections: Are Prescription Drug Pricing Reforms Losing Political Luster?

    US Presidential Elections: Are Prescription Drug Pricing Reforms Losing Political Luster?

    Aug 23 2024 
    • By Cathy Kelly

    Neither Kamala Harris nor Donald Trump mentioned drug pricing reforms in their presidential convention speeches.


  • PBMs and Vertical Integration: CBO Adds To Growing Concerns About Negative Impacts

    PBMs and Vertical Integration: CBO Adds To Growing Concerns About Negative Impacts

    Aug 21 2024 
    • By Sarah Karlin-Smith

    Congressional Budget Office responses to questions from US lawmakers on pharmacy benefit managers could add to the momentum for PBM reforms to go further than the current leading proposals.

  • Beyond BIOSECURE: Lawmakers Flag US Clinical Trial Partnerships With Chinese Military Hospitals

    Beyond BIOSECURE: Lawmakers Flag US Clinical Trial Partnerships With Chinese Military Hospitals

    Aug 20 2024 
    • By Cathy Kelly

    Letter to US FDA by a bipartisan group of House members cites clinical trials sponsored by Eli Lilly and Pfizer as examples of a widespread industry practice. But any legislation to curtail such practices is not expected to be part of the BIOSECURE Act.

  • FDA Disruption: If Trump Wins, Could Big Changes Be Coming?

    FDA Disruption: If Trump Wins, Could Big Changes Be Coming?

    Aug 20 2024 
    • By Ramsey Baghdadi

    The agency is clearly on the radar of former President Trump and his new coterie of tech moguls.

  • US FDA And The Election: Watch The Center Directors

    US FDA And The Election: Watch The Center Directors

    Aug 16 2024 
    • By Michael McCaughan

    A change in leadership of the US FDA device center is taking place with an eye towards stability in the longer term, but the upcoming elections could lead to more disruptive personnel changes.


  • US PBM Reform: ‘Bust Them Up’ A Theme For 2025?

    US PBM Reform: ‘Bust Them Up’ A Theme For 2025?

    Aug 02 2024 
    • By Laura Helbling

    Another House hearing again showcases the bipartisan desire to enact reforms to the US pharmacy benefit management sector. Legislators also sound ready to push for more significant actions than “transparency” measures would promise, but that means waiting until 2025.

  • VP Harris ‘Marches In’ To Presidential Campaign: Will Policy Change?

    VP Harris ‘Marches In’ To Presidential Campaign: Will Policy Change?

    Aug 01 2024 
    • By Ramsey Baghdadi

    The shake up in the US presidential campaign line up could have implications for future drug pricing policies. VP Kamala Harris has been an advocate for “march in” rights and could push that policy harder than incumbent President Joe Biden.

  • FDA Leadership Changes Tune On Pediatric Priority Review Voucher Benefit

    FDA Leadership Changes Tune On Pediatric Priority Review Voucher Benefit

    Jul 24 2024 
    • By Sarah Karlin-Smith

    As the reauthorization deadline nears, CDER and CBER leaders stressed that sunsetting the program would hurt pediatric rare disease development, while endorsing a new Democrat-proposed stick for rare disease research. 

  • PBM Execs Stay On Message Amid Growing US Congressional Frustration At Hearing

    PBM Execs Stay On Message Amid Growing US Congressional Frustration At Hearing

    Jul 24 2024 
    • By Cathy Kelly

    The House Oversight Committee held its third hearing on pharmacy benefit manager reforms in 14 months, but could not elicit an admission from executives that they are responsible for increasing drug prices.


  • Environmental Risk Assessments To Loom Larger In EU Drug Reviews

    Environmental Risk Assessments To Loom Larger In EU Drug Reviews

    Jul 23 2024 
    • By Ian Schofield

    In this final article in a series on the ongoing amendments to the pharmaceutical reform package, the Pink Sheet looks at the tougher environmental risk assessment requirements that pharma companies are likely to face in the not-too-distant future.

  • EU Pharma Reform, SPCs, Compulsory Licensing Among Parliament’s ‘Unfinished Business’

    EU Pharma Reform, SPCs, Compulsory Licensing Among Parliament’s ‘Unfinished Business’

    Jul 22 2024 
    • By Ian Schofield

    A number of legislative proposals will be coming under scrutiny at the newly constituted European Parliament in the coming months, including the pharma reform package and draft legislation on EU-level compulsory licensing and “unitary” supplementary protection certificates.

  • Slimmed-Down Obesity Drug Coverage In Medicare: First Step Or False Start?

    Slimmed-Down Obesity Drug Coverage In Medicare: First Step Or False Start?

    Jul 15 2024 
    • By Michael McCaughan

    A US House of Representatives bill to provide obesity drug coverage to a very select group of Medicare beneficiaries, passed only after Democrats debated whether the proposal is a “first step” towards broader coverage or a misstep counter to Medicare’s goals.

  • Project 2025 And The US FDA

    Project 2025 And The US FDA

    Jul 15 2024 
    • By Michael McCaughan

    A Trump-aligned think tank doesn’t have too much to say about the US FDA – which is probably a good thing for the agency. But it does reinforce the reality that abortion politics will continue to impact the agency – and that ties to industry may be a bipartisan area of concern.


  • Life After Chevron: User Fee Cycle May Help US FDA In Era Of Uncertainty

    Life After Chevron: User Fee Cycle May Help US FDA In Era Of Uncertainty

    Jul 13 2024 
    • By Michael McCaughan

    US federal agencies are entering a new era of uncertainty and increased litigation over their regulatory interpretations, but the FDA may benefit from the unique circumstances that have evolved through user fee legislation.

  • Accelerated Approval: ALS Drug Could Test New Congressional Directive On Survival

    Accelerated Approval: ALS Drug Could Test New Congressional Directive On Survival

    Jul 13 2024 
    • By Sarah Karlin-Smith

    Clene leadership spoke with the Pink Sheet about its push for accelerated approval for its ALS nanoparticle treatment. A new nudge from Congress asking the US FDA to consider survival data in accelerated approval could help.

  • Congress Pushes US FDA On Trial Diversity, Accelerated Approval In Approps Report

    Congress Pushes US FDA On Trial Diversity, Accelerated Approval In Approps Report

    Jul 10 2024 
    • By Sarah Karlin-Smith

    The House Appropriations Committee indicates in fiscal year 2025 appropriations report language that lawmakers will closely monitor the FDA’s implementation of clinical trial diversity action plans. 

  • New Zealand Gets Cracking On NZD$604m Drug Funding Boost; Starts Repealing Landmark Law

    New Zealand Gets Cracking On NZD$604m Drug Funding Boost; Starts Repealing Landmark Law

    Jul 05 2024 
    • By Neena Brizmohun

    Two targeted treatments for six different types of cancer and two antifungal drugs are the first products that Pharmac has proposed should be funded after it received a boost to its budget in June. Separately, the government is seeking feedback on a bill to repeal the sweeping new therapeutic products law that was passed by its predecessor.

Norstella India logo
Twitter feedfooter-block.linkedin-linkRSS feedPodcastPodcast

About

  • About UsOpens in new window
  • Meet the Team
  • AdvertiseOpens in new window
  • Contact Us

Account

  • My Account
  • My View
  • Email Preferences
  • Start Free TrialOpens in new window

More

  • Regulatory Trackers
  • Pink Sheet Perspectives
  • Regional Comparisons
  • Drug Review Profiles
Home
Terms and ConditionsOpens in new window
Privacy PolicyOpens in new window